Associate Professor of Medicine, University S Fla College of Medicine
Oncology
Dr. Scott J. Antonia, MD
|
|
Give Review
Scott J. Antonia, MD practices Oncology. He researched medicine at University of Connecticut School of Medicine. University of Connecticut School of Medicine is ranked 60/49 in Research/PrimaryCare. He over the years received 2 awards: "America's Top Doctors" and "America's Top Doctors for Cancer". Scott Antonia is also published. He has 76 publications published. The lastest publication: "Immunologic nonresponsiveness to tumors.' Scott Antonia accepts Medicare.
Publications
- Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patien...
- Immunotherapy in lung Cancer: "b7-bombers" and other new developments.
- Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell-based Vaccine for Refractory Lung Adenocarcinoma.
- The bottleneck effect in lung Cancer clinical trials.
- Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung Cancer.
- Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and Cancer associated fibroblasts inhibits their growth.
- Therapeutic regulation of myeloid-derived suppressor cells and immune response to Cancer vaccine in patients with extensive stage small cell lung Cancer.
- Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in Cancer.
- Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast Cancer tissue by immunohistochemistry.
- Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma.
- Building a long distance training program to enhance clinical Cancer research capacity in puerto rico.
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells.
- Advances in gene therapy for Malignant melanoma.
- Novel therapies for renal Cell carcinoma--an update.
- Gefitinib (ZD1839) in previously treated advanced non-small-cell lung Cancer: experience from a single institution.
- Current developments of immunotherapy in the clinic.
- Specific antitumour vaccine for renal Cancer.
- Arginase I production in the tumor microenvironment by mature myeloid Cells inhibits T-Cell receptor expression and antigen-specific T-Cell responses.
- Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung Cancer.
- All-trans-retinoic acid improves differentiation of myeloid cells and immune response in Cancer patients.
- Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during Cancer immunotherapy in mice.
- Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in Cancer.
- Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung Cancer.
- Hepatic portal venous gas in a patient with metastatic non-small cell lung Cancer on bevacizumab therapy: a case report and review of the literature.
- Phase I/II trial of tremelimumab in patients with metastatic Melanoma.
- Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung Cancer.
- Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
- Combined modality immunotherapy and chemotherapy: a new perspective.
- Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small Cell lu...
- Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small Cell and neuroendo...
- Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung Cancer.
- Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney Cancer and melanoma.
- Indoleamine 2,3-dioxygenase: is it an immune suppressor?
- Lipid accumulation and dendritic cell dysfunction in Cancer.
- Thymidylate synthase 1 (TS1) in-Situ protein expression predicts the survival of Ewing/PNET.
- A CD117 and CD34 immunoreactive sarcoma masquerading as a gastrointestinal stromal tumor: diagnostic pitfalls of ancillary studies in sarcoma.
- Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung Cancer cells through a caspase-independent mechanism mediated through AIF.
- Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic Cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid Tumors.
- INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung Cancer: observed association between immune response and enhanced chemotherapy effect.
- Systemic therapy for advanced hepatoCellular carcinoma: past, present, and future.
- An agonist antibody specific for CD40 induces dendritic Cell maturation and promotes autologous anti-tumour T-Cell responses in an in vitro mixed autologous tumour cel...
- Clinical activity and immune modulation in Cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
- A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander Cell line (GM.CD40L) in the formulation of autologous tumor Cell-based vaccines for c...
- Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung Cancer (NSCLC) who are 70 years of age or older.
- Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor Cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal Cell carcinoma.
- Surgical excision combined with autologous whole tumor Cell vaccination is an effective therapy for murine neuroblastoma.
- Combination of p53 Cancer vaccine with chemotherapy in patients with extensive stage small cell lung Cancer.
- A GM-CSF/CD40L producing Cell augments anti-tumor T Cell responses.
- Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic Cells in tumor-draining lymph nodes.
- Cell-based immune therapy for metastatic renal Cancer.
- Pattern of recruitment of immunoregulatory antigen-presenting Cells in malignant melanoma.
- Gene therapy for lung Cancer.
- Gene therapy for lung Cancer. An introduction.
- Potential regulatory function of human dendritic Cells expressing indoleamine 2,3-dioxygenase.
- Indoleamine 2,3-dioxygenase contributes to tumor Cell evasion of T Cell-mediated rejection.
- Phase I trial of a B7-1 (CD80) gene modified autologous tumor Cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal Cell carcinoma.
- Novel therapies for renal Cell carcinoma.
- B7-1 gene-modified tumor Cell vaccines.
- B7-1 gene-modified autologous tumor-Cell vaccines for renal-Cell carcinoma.
- Human cut-like repressor protein binds TGFbeta type II receptor gene promoter.
- Identification of an enhancer element in the mouse B7-1 promoter.
- Immunologic nonresponsiveness to Tumors.
- A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression.
- Renal ischemic-reperfusion injury in L-selectin-deficient mice.
- Cloning and partial characterization of the mouse B7-1 promoter.
- Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma Cells.
- Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small Cell carcinoma of the lung.
- Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein.
- B7-1 expression by a non-antigen presenting Cell-derived tumor.
- Adherence of tumor Cells to endothelial monolayers: inhibition by lymphokines.
- The elaboration of a small molecular weight cytostatic factor by lymphoblastoid lines and activated lymphocytes.
- Attachment of tumor Cells to endothelial monolayers: detection of surface molecules involved in Cell-Cell binding.
- A Phase I study of indoximod in patients with advanced malignancies.
Schools
University Of Connecticut School Of Medicine
Yale New Haven Hospital
Yale University School Of Med
Procedures Preformed
- Immunotherapy
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Oncology
Accepted Insurances
- Aetna
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access
- Group Plan PPO
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicaid
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
Yale-New Haven Hospital -
University of Connecticut School of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1669404091 | |
| NPPES Provider LastName | ANTONIA | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 290.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 42.0 | |
| Percent Opioid Claims | 14.48 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669404091 |
| Last Name Of The Provider | ANTONIA |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
Dr. Julio Lautersztain, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Gregoire Bergier, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Hugo F. Fernandez, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bryan McIver, MD |
|
Dr. Jhanelle Gray, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Frederick Locke, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Amit Mahipal, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Y K Peter Park, MD |
|
|
Dr. Adil Daud, MD
This Doctor is OpenDoctor Recommended.
|